Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2 / Phase 3INTERVENTIONAL

Fenofibrate in Ulcerative Colitis

Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.

Who May Be Eligible (Plain English)

Who May Qualify: - Age ≥ 18 years - Both males and females will be included - Negative pregnancy test and effective contraception. - Mild and moderate UC patients diagnosed and confirmed by an endoscope Who Should NOT Join This Trial: - Breastfeeding - Significant liver and kidney function abnormalities - Colorectal cancer patients - Other inflammatory bowel diseases (CD). - Patients with severe UC - Patients taking rectal or systemic steroids - Patients taking immunosuppressives or biological therapies - Addiction to alcohol and/or drugs - Known allergy to the Fenofibrate Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age ≥ 18 years * Both males and females will be included * Negative pregnancy test and effective contraception. * Mild and moderate UC patients diagnosed and confirmed by an endoscope Exclusion Criteria: * Breastfeeding * Significant liver and kidney function abnormalities * Colorectal cancer patients * Other inflammatory bowel diseases (CD). * Patients with severe UC * Patients taking rectal or systemic steroids * Patients taking immunosuppressives or biological therapies * Addiction to alcohol and/or drugs * Known allergy to the Fenofibrate

Treatments Being Tested

DRUG

Mesalamine

Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC

DRUG

Fenofibrate 160mg

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.

Locations (1)

Tanta Unuversity
Tanta, Egypt